Brief: Inventiva SA Says DMC Review Confirms Good Safety Profile Of Lanifibranor
16/05/2024 21:02
May 16 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES THE POSITIVE RECOMMENDATION OF THE
FOURTH
DMC OF THE NATIV3 PHASE III CLINICAL TRIAL WITH LANIFIBRANOR IN
PATIENTS WITH MASH/NASH
* INVENTIVA SA - DMC REVIEW CONFIRMS GOOD SAFETY PROFILE OF
LANIFIBRANOR
Source text for Eikon: ID:nGNX5k4wPQ
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030